4753
Pharmacoeconomic study of canagliflozin (invocana) therapy as a part of combined therapy for patients with type 2 diabetes mellitus
Study purpose: to determine whether canagliflozin is a pharmacoeconomically justified option to be included into therapy for patients with insufficient glycemic control and treated with metformin either as monotherapy administered in the maximum tolerated dose or as a part of a combined therapy with sulfonylurea derivatives taking into account the conditions existing in the Russian Federation.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Novikov I.V., Kulikov A. Yu., Pharmacoeconomic study of canagliflozin (invocana) therapy as a part of combined therapy for patients with type 2 diabetes mellitus // Pharmacoeconomics: theory and practice. - 2015. - Vol.3, №3. - P.55-61 DOI: https://doi.org/10.30809/phe.3.2015.6
Comments0